Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH
Sponsor: Medi-Tate Ltd.
Summary
A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study. Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.
Official title: One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-tate Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
149
Start Date
2018-02-18
Completion Date
2025-04-25
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
iTind
device implanted for 5-7 days
Locations (12)
Sydney Adventist Hospital Clinical School of the University of Sydney
Sydney, Australia
Hospital Center University De Bordeaux
Bordeaux, France
Hôpital Cochin
Paris, France
Hôpital Privé des Côtes d'Armor
Plérin, France
University Hospital Frankfurt
Frankfurt, Germany
Medical center - University of Freiburg
Freiburg im Breisgau, Germany
AOU di Catanzaro
Catanzaro, Italy
Azienda Ospedaliera Universitaria San Martino
Genova, Italy
Sant'Andrea Hospital
Rome, Italy
San Orbessano
Turin, Italy
Clínica CEMTRO Ventisquero la Condesa
Madrid, Spain
Cantonal Hospital St. Gallen
Sankt Gallen, Switzerland